+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biosimilar Monoclonal Antibodies Market - Global Forecast 2026-2032- Product Image
Biosimilar Monoclonal Antibodies Market - Global Forecast 2026-2032- Product Image
New

Biosimilar Monoclonal Antibodies Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 184 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010903
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The biosimilar monoclonal antibodies market is rapidly transforming the landscape of global healthcare access, as regulatory clarity, clinical adoption, and innovative commercial models shape new opportunities and risks for senior decision-makers in this dynamic sector.

Market Snapshot: Growth Trajectory for Biosimilar Monoclonal Antibodies

The biosimilar monoclonal antibodies market is experiencing robust expansion, growing from USD 11.60 billion in 2025 to USD 14.22 billion in 2026. Forecasts indicate ongoing double-digit annual gains at a CAGR of 24.04%, with the market set to reach USD 52.44 billion by 2032. This pattern highlights intensifying competition, increased regulatory support, and greater integration into clinical practice. Senior stakeholders should anticipate a changing landscape where procurement, regulatory alignment, and patient access strategies become critical to market performance.

Biosimilar Monoclonal Antibodies Market: Scope & Segmentation

This report delivers comprehensive insights into the biosimilar monoclonal antibodies sector, mapping key drivers and commercial pathways that define growth and positioning. Market segmentation and technology adoption are analyzed with attention to relevance for strategic decision-making:

  • Molecule Classes: Includes anti-CD20 agents, anti-HER2 therapies, and anti-VEGF molecules such as aflibercept, bevacizumab, ranibizumab, as well as colony stimulating factors (e.g., filgrastim, pegfilgrastim), and TNF inhibitors including adalimumab, etanercept, and infliximab.
  • Therapeutic Indications: Assesses market reach in oncology (breast, colorectal, lung cancers), immunology (rheumatoid arthritis, inflammatory bowel diseases, plaque psoriasis, psoriatic arthritis, juvenile idiopathic arthritis), and hematology care.
  • Dosage Forms: Evaluates adoption trends of liquid solutions, vials, prefilled pens, and syringes with an emphasis on device design and its effects on clinical workflows and patient preferences.
  • Distribution Channels: Examines hospital pharmacies (public and private), specialty clinics, retail channels, and the growing importance of online platforms to support outpatient and home care delivery.
  • End-User Segments: Reviews clinical and procurement behaviors across hospital pharmacies, retail stores, and specialty settings in oncology, dermatology, and rheumatology.
  • Geographic Regions: Explores strategic dynamics in the Americas, Europe, Middle East & Africa, and Asia-Pacific, including varied regulatory frameworks and manufacturing footprints.
  • Technology Landscape: Analyzes adoption of single-use manufacturing technologies, modular production platforms, digital patient-support programs, and enhanced pharmacovigilance systems.

Key Takeaways: Biosimilar Monoclonal Antibodies Market Trends

  • Regulatory developments are paving the way for biosimilar monoclonal antibodies to enter national formularies, supported by improved interchangeability and enhanced post-market monitoring that strengthens physician and payer confidence.
  • Payers and health systems are prioritizing value-based procurement and extended contracts, which encourages manufacturers to focus on reliable supply, integrated pharmacovigilance, and clear outcomes reporting as key differentiators.
  • Uptake in hospital and community settings continues to accelerate, driven by real-world evidence and innovations in alternative dosage forms that enable convenient administration in home and outpatient environments.
  • Expansion of distribution models, such as online pharmacies and remote delivery, is improving patient reach, particularly for maintenance therapies across chronic disease areas, while supporting operational flexibility for providers.
  • Resilience strategies, including agile manufacturing infrastructure, regionalized supply chains, and diversified sourcing, are critical as manufacturers seek to manage operational risks and adapt to shifting global dynamics.

Tariff Impact: Responding to New US Trade Measures

The 2025 introduction of new US tariff measures is compelling manufacturers to re-examine global supply chains for biosimilar monoclonal antibodies. Companies are revising sourcing strategies for essential components, scaling regional manufacturing capacity, and seeking policy exemptions to protect access to critical medicines. This environment places a premium on coordinated inventory management, localized fill-finish operations, and collaboration with payers and providers to mitigate disruptions and navigate changing cost structures.

Methodology & Data Sources

Research findings are built on primary interviews with clinical, regulatory, and commercial stakeholders, supported by in-depth review of regulatory documentation and public filings. Rigorous data triangulation and expert input ensure validated, actionable insights for each market segment and geography.

Why This Report Matters

  • Delivers proven strategies to address complex payer procurement models, changing regulatory frameworks, and developments in competitive practice.
  • Empowers senior leaders with data on manufacturing agility, channel-specific adoption, and innovation pathways vital for forward-looking planning.
  • Facilitates efficient resource decisions by clarifying risk exposures tied to tariffs, supply chain challenges, and evolving end-user expectations.

Conclusion

Long-term commercial success in the biosimilar monoclonal antibodies market will depend on strategic coordination across manufacturing, evidence generation, and tailored execution. Senior leaders who drive agility and patient-focused solutions will position their organizations for enduring market relevance.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Biosimilar Monoclonal Antibodies Market, by Molecule Class
8.1. Anti Vascular Endothelial Growth Factor
8.1.1. Aflibercept
8.1.2. Bevacizumab
8.1.3. Ranibizumab
8.2. Colony Stimulating Factors
8.2.1. Filgrastim
8.2.2. Pegfilgrastim
8.3. Tnf Inhibitors
8.3.1. Adalimumab
8.3.2. Etanercept
8.3.3. Infliximab
9. Biosimilar Monoclonal Antibodies Market, by Indication
9.1. Inflammatory Bowel Disease
9.1.1. Crohn Disease
9.1.2. Ulcerative Colitis
9.2. Neutropenia
9.3. Oncology
9.3.1. Breast Cancer
9.3.2. Colorectal Cancer
9.3.3. Lung Cancer
9.4. Psoriasis
9.4.1. Plaque Psoriasis
9.4.2. Psoriatic Arthritis
9.5. Rheumatoid Arthritis
9.5.1. Adult Rheumatoid Arthritis
9.5.2. Juvenile Idiopathic Arthritis
10. Biosimilar Monoclonal Antibodies Market, by Dosage Form
10.1. Liquid Solution
10.2. Prefilled Pen
10.3. Prefilled Syringe
10.4. Vial
10.4.1. Liquid Vial
10.4.2. Lyophilized Powder
11. Biosimilar Monoclonal Antibodies Market, by Distribution Channel
11.1. Offline
11.2. Online
12. Biosimilar Monoclonal Antibodies Market, by End User
12.1. Hospital Pharmacy
12.1.1. Private Hospital
12.1.2. Public Hospital
12.2. Retail Pharmacy
12.2.1. Chain Pharmacy
12.2.2. Independent Pharmacy
12.3. Specialty Clinics
12.3.1. Dermatology Clinic
12.3.2. Oncology Center
12.3.3. Rheumatology Clinic
13. Biosimilar Monoclonal Antibodies Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Biosimilar Monoclonal Antibodies Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Biosimilar Monoclonal Antibodies Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Biosimilar Monoclonal Antibodies Market
17. China Biosimilar Monoclonal Antibodies Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Alvotech
18.6. Amgen Inc.
18.7. Bio-Thera Solutions, Ltd.
18.8. Biocon Ltd.
18.9. Boehringer Ingelheim International GmbH
18.10. Celltrion, Inc.
18.11. Coherus BioSciences, Inc.
18.12. Dr. Reddy's Laboratories Ltd.
18.13. Formycon AG
18.14. Fresenius Kabi AG
18.15. Intas Pharmaceuticals Ltd.
18.16. mAbxience Research SL
18.17. Merck KGaA
18.18. Pfizer Inc.
18.19. Samsung Bioepis Co., Ltd.
18.20. Sandoz International GmbH
18.21. Shanghai Henlius Biotech, Inc.
18.22. Stada Arzneimittel AG
18.23. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY FILGRASTIM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY FILGRASTIM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PEGFILGRASTIM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PEGFILGRASTIM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ETANERCEPT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ETANERCEPT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CROHN DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CROHN DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CROHN DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY NEUTROPENIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY NEUTROPENIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY NEUTROPENIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PLAQUE PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PLAQUE PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIATIC ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIATIC ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADULT RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADULT RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADULT RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LIQUID SOLUTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LIQUID SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LIQUID SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREFILLED PEN, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREFILLED PEN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREFILLED PEN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LIQUID VIAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LIQUID VIAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LIQUID VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DERMATOLOGY CLINIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DERMATOLOGY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DERMATOLOGY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY CENTER, BY REGION, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY CENTER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOLOGY CLINIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOLOGY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOLOGY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 148. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 149. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 150. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2032 (USD MILLION)
TABLE 151. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2032 (USD MILLION)
TABLE 152. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 153. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 154. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 155. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 156. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 157. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 158. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 159. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 160. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 161. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 162. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 163. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 164. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 165. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 167. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2032 (USD MILLION)
TABLE 168. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2032 (USD MILLION)
TABLE 169. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 170. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 171. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 172. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 173. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 174. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 175. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 176. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 177. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 178. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 179. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 180. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 181. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 182. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 183. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 184. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2032 (USD MILLION)
TABLE 185. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2032 (USD MILLION)
TABLE 186. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 187. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 188. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 189. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 190. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 191. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 192. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 193. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 194. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 195. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 196. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 197. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 198. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2032 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2032 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 216. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 218. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2032 (USD MILLION)
TABLE 219. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2032 (USD MILLION)
TABLE 220. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 221. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 222. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 223. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 224. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 225. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 226. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 227. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 228. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 229. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 230. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 231. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 232. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 233. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 234. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 235. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2032 (USD MILLION)
TABLE 236. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2032 (USD MILLION)
TABLE 237. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 238. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 239. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 240. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 241. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 242. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 243. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 244. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 245. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 246. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 247. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 248. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 249. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 250. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 251. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 252. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2032 (USD MILLION)
TABLE 253. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2032 (USD MILLION)
TABLE 254. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 255. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 256. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 257. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 258. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 259. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 260. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 261. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 262. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 263. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 264. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 265. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 266. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 267. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 268. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 269. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2032 (USD MILLION)
TABLE 270. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2032 (USD MILLION)
TABLE 271. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 272. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 273. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 274. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 275. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 276. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
TABLE 277. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 278. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
TABLE 279. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 280. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 281. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 282. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 283. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARK

Companies Mentioned

The key companies profiled in this Biosimilar Monoclonal Antibodies market report include:
  • Alvotech
  • Amgen Inc.
  • Bio-Thera Solutions, Ltd.
  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Celltrion, Inc.
  • Coherus BioSciences, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Formycon AG
  • Fresenius Kabi AG
  • Intas Pharmaceuticals Ltd.
  • mAbxience Research SL
  • Merck KGaA
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Shanghai Henlius Biotech, Inc.
  • Stada Arzneimittel AG
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages184
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 14.22 Billion
Forecasted Market Value ( USD ) by 2032 $ 52.44 Billion
Compound Annual Growth Rate24.0%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Biosimilars Market - Products, Applications and Regulations - Product Image

Biosimilars Market - Products, Applications and Regulations

  • Report
  • 227 Pages
  • Global
From
Biosimilar Monoclonal Antibody Market - Global Strategic Business Report - Product Image

Biosimilar Monoclonal Antibody Market - Global Strategic Business Report

  • Report
  • 235 Pages
  • Global
From
Oncology Biosimilars Market - Product Image

Oncology Biosimilars Market

  • Report
  • 150 Pages
  • Global
From
Biosimilars Market Outlook, 2030 - Product Image

Biosimilars Market Outlook, 2030

  • Report
  • 191 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market Report 2025 - Product Image

Biosimilar Monoclonal Antibodies Market Report 2025

  • Report
  • 250 Pages
  • Global
From

About the Monoclonal Antibodies Market

Biosimilar Monoclonal Antibodies (mAbs) are biotechnological products that are similar to existing monoclonal antibodies (mAbs) that are already approved for use in humans. Biosimilar mAbs are developed using recombinant DNA technology and are designed to have the same structure and function as the original mAbs. Biosimilar mAbs are used to treat a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. They are also used in research and development of new treatments. The biosimilar mAbs market is growing rapidly due to the increasing demand for mAbs in the treatment of various diseases. The market is expected to continue to grow as more mAbs are developed and approved for use in humans. Additionally, the increasing demand for mAbs in research and development is expected to drive the growth of the market. Some companies in the biosimilar mAbs market include Amgen, Biogen, Merck, Pfizer, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.